阿托伐他汀治疗高脂血症的疗效及安全性观察

Curative Effect and Safety Observation of Atorvastatin for Hyperlipidemia Treatment

目的探讨老年冠心病患者持续应用阿托伐他汀治疗高脂血症的疗效,并观察其安全性。方法选取2010年1月1日至2010年12月31日我院收治的冠心病伴有高脂血症的老年患者98例,随机分为观察组(58例)和对照组(40例),两组均行常规内科治疗,实验组同时持续口服阿托伐他汀钙,10 mg/d。两组治疗疗程均为12周,观察治疗期间血脂状况,肝肾功能状况,心绞痛发作次数及其他不良反应等。结果治疗6周后,观察组总胆固醇(TC)、低密度脂蛋白(LDL-C)和三酰甘油(TG)与治疗前相比显著下降;治疗12周后,TC、LDL-C仍有进一步下降趋势;而对照组治疗前后TC、LDL-C和TG水平比较差异无统计学意义(P>0.05);两组治疗6周后和12周后心绞痛平均发作次数比较差异均有统计学意义(P<0.05)。结论阿托伐他汀能快速降低老年冠心病患者的血脂水平,有效缓解冠心病患者临床症状,肝肾功能损伤小,无肌溶解不良反应,安全性强,具有良好的临床应用前景。

Objective To study the efficacy and safety of continuous use of atorvastatin for hyperlipi- demia in elderly patients with coronary heart disease. Methods From January 1st of 2010 to December 31st of 2010,98 elderly patients with coronary heart disease in our hospital were selected and randomly divided into observation group（ 58 cases） and control group（40 eases）. Both groups underwent routine medical treat- ment,and observation group continued to take atorvastatin calcium 10mg/d at the meantime, while control group did not. Treatment was 12 weeks for both groups. Lipid profile,liver and kidney function, heart failure, the number of angina pectoris attacks and other adverse reactions of the two groups during treatment were ob- served. Results After 6 weeks treatment, the TC, LDL-C and TG of experimental group were significantly decreased;after 12 weeks, TC and LDL-C showed further downward trend. While TC, LDL-C and TG level of control group had no significant difference before and after treatment （P 〉 0.05 ）, the attacks number of heart failure and angina pectoris increased than before treatment （ P 〈 0.05 ）. Conclusion Atorvastatin can de- crease the lipid levels of elderly patients with coronary artery disease, effectively released the clinical symp- toms, with little damage to liver and kidney function, without myolysis, which is safe and has good prospects for clinical application.